Abstract
Introduction: Post-traumatic stress disorder (PTSD) is a frequent and disabling condition that occurs after exposure to a traumatic event, and Selective Serotonin Reuptake Inhibitors (SSRIs) are considered the first-line treatment approach for this disorder. However, a large proportion of patients remain symptomatic and other pharmacological agents have been investigated, based on the understanding of the underlying biological dysfunctions of PTSD.
Methods: We conducted a review of the literature on the pharmacological options for PTSD other than the antidepressants, using MedLine and Web of Science databases, with search terms including the pharmacologic class of each agent plus PTSD, or pharmacotherapy, or fear conditioning. The literature review covered articles published until august 2012, including reviews and original articles.
Results: Agents like antipsychotics, anticonvulsants, benzodiazepines, anti-adrenergic agents, have been studied in randomized clinical trials (RCTs), with general positive results for antipsychotics, especially as adjunct therapy, and for prazosin for sleep-related disturbances. However, one important target for novel medications is the modulation of the fear conditioning process, through the alteration of retrieval/reconsolidation or enhancement of fear extinction. This is traditionally targeted in prolonged exposure therapy, but pre-clinical findings from studies investigating agents like propanolol, clonidine, N-Methyl-D-aspartic Acid Receptor (NMDAR) compounds, 3,4-methylenedioxy-N-methylamphetamine (MDMA) and cannabinoids, indicate promising results in affecting the fear conditioning process and thus improving PTSD core symptoms.
Discussion: Antipsychotics can be considered a reasonable alternative option to PTSD, with the largest body of evidence for risperidone, even though larger RCTs are warranted. Prazosin is also a promising agent, especially for sleep-related disturbances, while anticonvulsants and benzodiazepines lack empirical support. However, the most promising area for pharmacotherapy in PTSD is the modulation of the fear conditioning process, through agents used in adjunct to exposure therapy.
Keywords: Adrenoreceptor antagonists, anticonvulsants, antipsychotics, benzodiazepines, fear conditioning, pharmacotherapy, PTSD.
Current Clinical Pharmacology
Title:Non-Antidepressant Long-term Treatment in Post-Traumatic Stress Disorder (PTSD)
Volume: 10 Issue: 2
Author(s): Hala Kerbage and Sami Richa
Affiliation:
Keywords: Adrenoreceptor antagonists, anticonvulsants, antipsychotics, benzodiazepines, fear conditioning, pharmacotherapy, PTSD.
Abstract: Introduction: Post-traumatic stress disorder (PTSD) is a frequent and disabling condition that occurs after exposure to a traumatic event, and Selective Serotonin Reuptake Inhibitors (SSRIs) are considered the first-line treatment approach for this disorder. However, a large proportion of patients remain symptomatic and other pharmacological agents have been investigated, based on the understanding of the underlying biological dysfunctions of PTSD.
Methods: We conducted a review of the literature on the pharmacological options for PTSD other than the antidepressants, using MedLine and Web of Science databases, with search terms including the pharmacologic class of each agent plus PTSD, or pharmacotherapy, or fear conditioning. The literature review covered articles published until august 2012, including reviews and original articles.
Results: Agents like antipsychotics, anticonvulsants, benzodiazepines, anti-adrenergic agents, have been studied in randomized clinical trials (RCTs), with general positive results for antipsychotics, especially as adjunct therapy, and for prazosin for sleep-related disturbances. However, one important target for novel medications is the modulation of the fear conditioning process, through the alteration of retrieval/reconsolidation or enhancement of fear extinction. This is traditionally targeted in prolonged exposure therapy, but pre-clinical findings from studies investigating agents like propanolol, clonidine, N-Methyl-D-aspartic Acid Receptor (NMDAR) compounds, 3,4-methylenedioxy-N-methylamphetamine (MDMA) and cannabinoids, indicate promising results in affecting the fear conditioning process and thus improving PTSD core symptoms.
Discussion: Antipsychotics can be considered a reasonable alternative option to PTSD, with the largest body of evidence for risperidone, even though larger RCTs are warranted. Prazosin is also a promising agent, especially for sleep-related disturbances, while anticonvulsants and benzodiazepines lack empirical support. However, the most promising area for pharmacotherapy in PTSD is the modulation of the fear conditioning process, through agents used in adjunct to exposure therapy.
Export Options
About this article
Cite this article as:
Kerbage Hala and Richa Sami, Non-Antidepressant Long-term Treatment in Post-Traumatic Stress Disorder (PTSD), Current Clinical Pharmacology 2015; 10 (2) . https://dx.doi.org/10.2174/157488471002150723122127
DOI https://dx.doi.org/10.2174/157488471002150723122127 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Gut Microbiota and Alcoholic Liver Disease
Reviews on Recent Clinical Trials Prognostic Value of White Blood Cell Counts and C-reactive Protein in Acute Ischemic Stroke Patients After Intravenous Thrombolysis
Current Neurovascular Research Antenatal Maternal Antidepressants Drugs Affect S100B Concentrations in Fetal-Maternal Biological Fluids
CNS & Neurological Disorders - Drug Targets Use of Biochemical and Microscopic Techniques to Determine Enhanced Skin Permeation of Nanovesicles: A Mechanistic Study
Pharmaceutical Nanotechnology Fibrinolysis: The Key to New Pathogenetic Mechanisms
Current Medicinal Chemistry Inhibitors of Acyl-Coenzyme A: Cholesterol Acyltransferase
Current Drug Targets - Cardiovascular & Hematological Disorders Age-related Changes in Respiratory Function and Daily Living. A Tentative Model Including Psychosocial Variables, Respiratory Diseases and Cognition
Current Aging Science Effects of Memantine on Event-Related Potentials in Alzheimer’s Disease Under Donepezil Treatment
Neuroscience and Biomedical Engineering (Discontinued) Electromagnetic Field in Alzheimer’s Disease: A Literature Review of Recent Preclinical and Clinical Studies
Current Alzheimer Research Meet Our Editorial Board Member
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Sigma-1 Receptor Chaperones and Diseases
Central Nervous System Agents in Medicinal Chemistry Effect of Synthetic Cannabinoid HU210 on Memory Deficits and Neuropathology in Alzheimers Disease Mouse Model
Current Alzheimer Research Neural Correlates of Default Mode Network Connectivity in Children with Attention Deficit and Hyperactivity Disorder
Current Medical Imaging Functions of Antimicrobial Peptides in Vertebrates
Current Protein & Peptide Science Aligned Expression of IFI16 and STING Genes in RRMS Patients’ Blood
Endocrine, Metabolic & Immune Disorders - Drug Targets Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Editorial [Hot Topic: Pharmacogenomics: Achievements, Challenges and Prospects, for Patients, Pharmaceutical Industries and Healthcare Systems (Guest Editor: Despina Sanoudou)]
Current Pharmaceutical Design Metabolic Fate of Endocannabinoids
Current Neuropharmacology Cardiac Remodeling and Exercise Training in Hypertension
Current Hypertension Reviews